Skip to content
BIO is expanding its work to defend IP
When a biotech firm sells investors on the promise of a new drug, what they are really selling is the intellectual property behind their […]
BIO is expanding its work to defend IP Read More »
BIO kicks off ‘Fight of Our Lives,’ highlighting urgency of biotech progress at Axios event
As biotech celebrates its 50th year, we are locked in “the fight of our lives” to ensure patients get more of the medical innovations
BIO expert: Future of biotech depends on competing with China, updating FDA
Ensuring a brighter future for U.S. biotech requires modernizing the Food and Drug Administration (FDA) and addressing challenges from China, according to Kelly Seagraves,
BIO expert: Future of biotech depends on competing with China, updating FDA Read More »
BIO CEO hails congressional report on threat of China dominating biotech
A year after a congressional commission urged strategic action to prevent China from replacing America as the world leader in biotechnology, we still have
BIO CEO hails congressional report on threat of China dominating biotech Read More »
BIO Board member advises Congress on China’s clinical trial competition
China gains a huge advantage in biotech competition by speeding up clinical trials, and America must respond, a member of the Board of the
BIO Board member advises Congress on China’s clinical trial competition Read More »
BIO on the American Road in Puerto Rico: ‘Medicine Cabinet’ ready to reshore
Known as “America’s Medicine Cabinet,” Puerto Rico is working to maintain its leadership in U.S. biotech production by becoming a hub for reshoring pharmaceutical
BIO on the American Road in Puerto Rico: ‘Medicine Cabinet’ ready to reshore Read More »
BIO warns MFN models are illegal, ineffective, and a threat to innovation
Proposals to let decisions by other countries control American drug prices are illegal, would reduce the availability of innovative new treatments, and fail to
BIO warns MFN models are illegal, ineffective, and a threat to innovation Read More »
BIO CEO testifies in hearing highlighting PBMs’ impact on drug prices
Pharmacy benefit managers (PBMs) were identified as a major driver behind higher prescription drug costs in a congressional hearing that featured testimony from BIO
BIO CEO testifies in hearing highlighting PBMs’ impact on drug prices Read More »
NIH Director says no studies link vaccines and autism in hearing on modernization
National Institutes of Health (NIH) Director Jay Bhattacharya acknowledged there are no studies indicating a link between any vaccine and autism as Senators pushed
NIH Director says no studies link vaccines and autism in hearing on modernization Read More »
BIO lauds passage of PPRV reauthorization and legislation on PBM reform
The Biotechnology Innovation Organization (BIO) hailed inclusion of a bill to encourage new treatments for children with rare diseases and measures targeting reform of
BIO lauds passage of PPRV reauthorization and legislation on PBM reform Read More »